Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials

Journal of Perinatology volume 29, pages S38–S43 (2009)Cite this article

Abstract

Animal-derived surfactants, as well as synthetic surfactants, have been extensively evaluated in the treatment of respiratory distress syndrome (RDS) in preterm infants. Three commonly available animal-derived surfactants in the United States include beractant (BE), calfactant (CA) and poractant alfa (PA). Multiple comparative studies have been performed using these three surfactants. Prospective as well as retrospective studies comparing BE and CA have shown no significant differences in clinical or economic outcomes. Randomized, controlled clinical trials have shown that treatment with PA is associated with rapid weaning of oxygen and ventilatory pressures, fewer additional doses, cost benefits and survival advantage when compared with BE or CA. Recently, a study using an administrative database that included over 20 000 preterm infants has shown a significant decrease in mortality and cost benefits in favor of PA, when compared with BE or CA. Differences in outcomes between these animal-derived surfactants may be related to a higher amount of phospholipids and plasmalogens in PA. To date, animal-derived surfactants seem to be better than synthetic surfactants during the acute phase of RDS and in decreasing neonatal mortality. Further studies are needed comparing animal-derived surfactants with the newer generation of synthetic surfactants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Martin JA, Kung HC, Mathews TJ, Hoyert DL, Strobino DM, Guyer B et al. Annual summary of vital statistics: 2006. Pediatrics 2008; 121 (4): 788–801.

    Article  Google Scholar 

  2. Slattery MM, Morrison JJ . Preterm delivery. Lancet 2002; 360: 1489–1497.

    Article  Google Scholar 

  3. Tolle A, Meier W, Rudiger M, Hofmann KP, Rustow B . Effect of cholesterol and surfactant protein B on the viscosity of phospholipid mixtures. Chem Phys Lipids 2002; 114: 159–168.

    Article  CAS  Google Scholar 

  4. Tolle A, Meier W, Greune G, Rudiger M, Hofmann KP, Rustow B . Plasmalogens reduce the viscosity of surfactant-like phospholipid monolayer. Chem Phys Lipids 1999; 100: 81–87.

    Article  CAS  Google Scholar 

  5. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1993; 123: 757–766.

    Article  CAS  Google Scholar 

  6. Alvarado M, Hingre R, Hakason D, Gross S . Clinical trial of Survanta versus Exosurf in infants <1500 g with respiratory distress syndrome. Pediatr Res 1993; 33: 314A.

    Google Scholar 

  7. Pearlman SA, Leef KH, Stefano JL, Speer ML, Esterly KL . A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS. Pediatr Res 1993; 33: 340A.

    Google Scholar 

  8. Sehgal SS, Ewing CK, Richards T, Taeusch HW . Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc 1994; 86: 46–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Vermont-Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome Vermont-Oxford Neonatal Network. Pediatrics 1996; 97: 1–6.

    Google Scholar 

  10. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996; 128: 396–406.

    Article  CAS  Google Scholar 

  11. Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings NJ, Jung AL et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997; 100: 39–50.

    Article  CAS  Google Scholar 

  12. Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV . Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol 1997; 17: 455–460.

    CAS  PubMed  Google Scholar 

  13. da Costa DE, Pai MG, Al Khusaiby SM . Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatr Pulmonol 1999; 27: 312–317.

    Article  CAS  Google Scholar 

  14. Rollins M, Jenkins J, Tubman R, Corkey C, Wilson D . Comparison of clinical responses to natural and synthetic surfactants. J Perinat Med 1993; 21: 341–347.

    Article  CAS  Google Scholar 

  15. Kukkonen AK, Virtanen M, Jarvenpaa AL, Pokela ML, Ikonen S, Fellman V . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr 2000; 89: 556–561.

    Article  CAS  Google Scholar 

  16. Ainsworth SB, Beresford MW, Milligan DW, Shawn NJ, Matthews JN, Fenton AC et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks’ gestation: a randomised trial. Lancet 2000; 355: 1387–1392.

    Article  CAS  Google Scholar 

  17. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115 (4): 1018–1029.

    Article  Google Scholar 

  18. Sinha SK, Lacaze-Masmonteil T, Soler A, Wiswell TE, Gadzinowski J, Hajdu J et al. A multicenter, randomized, controlled trial of Lucinactant versus Poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030–1038.

    Article  Google Scholar 

  19. Moya F, Sinha S, Gadzinowski J, D’Agostino R, Segal R, Guardia C et al., STAR Study Investigators. One-year follow up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter, randomized, controlled trials. Pediatrics 2007; 119: e1361–e1370.

    Article  Google Scholar 

  20. Engle WA, The Committee on Fetus Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121: 419–432.

    Article  Google Scholar 

  21. Dargaville PA, Mills JM . Surfactant therapy for meconium aspiration syndrome: current status. Drugs 2005; 65 (18): 2569–2591.

    Article  CAS  Google Scholar 

  22. Taeush W, Lu K, Ramirez-Schrempp D . Improving pulmonary surfactants. Acta Pharmacol Sin 2002; 23: S11–S15.

    Google Scholar 

  23. Rudiger M, Tolle A, Meier W, Rustow B . Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am J Physiol Lung Cell Mol Physiol 2005; 288: L379–L383.

    Article  Google Scholar 

  24. Rudiger M, von Baehr A, Haupt R, Wauer RR, Rustow B . Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med 2000; 28: 1572–1577.

    Article  CAS  Google Scholar 

  25. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997; 100: 31–38.

    Article  CAS  Google Scholar 

  26. Bloom BT, Clark RH . Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics 2005; 116: 392–399.

    Article  Google Scholar 

  27. Speer CP, Gefeller O, Groneck P, Laufkötter E, Roll C, Hanssler L et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 1995; 72: F8–F13.

    Article  CAS  Google Scholar 

  28. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C . Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr 2003; 162: 476–480.

    Article  CAS  Google Scholar 

  29. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K . A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004; 21: 109–119.

    Article  Google Scholar 

  30. Malloy CA, Nicoski P, Muraskas JK . A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005; 94: 779–784.

    Article  Google Scholar 

  31. Clark RH, Auten RL, Peabody J . A comparison of the outcomes of neonates treated with two different natural surfactants. J Pediatr 2001; 139: 828–831.

    Article  CAS  Google Scholar 

  32. Ramanathan R, Saunders WB, Lavin PT, Sekar KC, Ernst FR, Bhatia J . Mortality differences among preterm neonates treated with three different natural surfactants: analyses from a large national database. Acta Pediatr 2007; 96 (Suppl 456): 107.

    Google Scholar 

  33. Halliday HL . History of surfactant from 1980. Biol Neonate 2005; 87: 317–322.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neonatal Medicine, Department of Pediatrics, Women's and Children's Hospital and Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    R Ramanathan

Authors
  1. R Ramanathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Ramanathan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramanathan, R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. J Perinatol 29 (Suppl 2), S38–S43 (2009). https://doi.org/10.1038/jp.2009.31

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jp.2009.31

Keywords

This article is cited by

Search

Advanced search

Quick links